Chemokines provide signals for activation and recruitment of effector cells into sites of inflammation, acting via specific G protein–coupled receptors. However, in vitro data demonstrating the presence of multiple ligands for a given chemokine receptor, and often multiple receptors for a given chemokine, have led to concerns of biologic redundancy. Here we show that acute cardiac allograft rejection is accompanied by progressive intragraft production of the chemokines interferon (IFN)-γ–inducible protein of 10 kD (IP-10), monokine induced by IFN-γ (Mig), and IFN-inducible T cell α chemoattractant (I-TAC), and by infiltration of activated T cells bearing the corresponding chemokine receptor, CXCR3. We used three in vivo models to demonstrate a role for CXCR3 in the development of transplant rejection. First, CXCR3-deficient (CXCR3−/−) mice showed profound resistance to development of acute allograft rejection. Second, CXCR3−/− allograft recipients treated with a brief, subtherapeutic course of cyclosporin A maintained their allografts permanently and without evidence of chronic rejection. Third, CXCR+/+ mice treated with an anti-CXCR3 monoclonal antibody showed prolongation of allograft survival, even if begun after the onset of rejection. Taken in conjunction with our findings of CXCR3 expression in rejecting human cardiac allografts, we conclude that CXCR3 plays a key role in T cell activation, recruitment, and allograft destruction.
Skip Nav Destination
Article navigation
20 November 2000
Brief Definitive Report|
November 20 2000
Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection
Wayne W. Hancock,
Wayne W. Hancock
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Search for other works by this author on:
Bao Lu,
Bao Lu
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Wei Gao,
Wei Gao
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Search for other works by this author on:
Vilmos Csizmadia,
Vilmos Csizmadia
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Search for other works by this author on:
Kerrie Faia,
Kerrie Faia
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Search for other works by this author on:
Jennifer A. King,
Jennifer A. King
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Search for other works by this author on:
Stephen T. Smiley,
Stephen T. Smiley
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Search for other works by this author on:
Mai Ling,
Mai Ling
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Norma P. Gerard,
Norma P. Gerard
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Craig Gerard
Craig Gerard
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Wayne W. Hancock
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Bao Lu
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Wei Gao
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Vilmos Csizmadia
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Kerrie Faia
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Jennifer A. King
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Stephen T. Smiley
aMillennium Pharmaceuticals, Incorporated, Cambridge, Massachusetts 02139
Mai Ling
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Norma P. Gerard
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Craig Gerard
bPerlmutter Laboratory, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115
Received:
September 07 2000
Accepted:
September 19 2000
Online ISSN: 1540-9538
Print ISSN: 0022-1007
© 2000 The Rockefeller University Press
2000
The Rockefeller University Press
J Exp Med (2000) 192 (10): 1515–1520.
Article history
Received:
September 07 2000
Accepted:
September 19 2000
Citation
Wayne W. Hancock, Bao Lu, Wei Gao, Vilmos Csizmadia, Kerrie Faia, Jennifer A. King, Stephen T. Smiley, Mai Ling, Norma P. Gerard, Craig Gerard; Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection. J Exp Med 20 November 2000; 192 (10): 1515–1520. doi: https://doi.org/10.1084/jem.192.10.1515
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement